IN8bio, Inc. develops gamma-delta (γδ) T cell therapies and γδ T cell engagers for cancer and autoimmune diseases. Company news centers on clinical and preclinical pipeline updates, including DeltEx Drug-Resistant Immunotherapy γδ T cells in newly diagnosed glioblastoma, INB-100 allogeneic γδ T cells for high-risk leukemias after haploidentical stem cell transplantation, and γδ T cell engager work for oncology and autoimmune indications.
Recurring updates also cover financial results, clinical data presentations at medical meetings, R&D communications, financing activity, Nasdaq inducement grants, and leadership or board changes. The company operates as a clinical-stage biopharmaceutical issuer with common stock traded on Nasdaq under INAB.
IN8bio (INAB) granted a new employee a stock option covering 60,000 common shares, with a grant date of October 1, 2026.
The Compensation Committee approved the nonqualified option under the 2026 Inducement Plan as an employment inducement under Nasdaq Listing Rule 5635(c)(4). Vesting runs over four years: 25% vests on the first anniversary of the employee’s start date, and the remainder vests in 36 equal monthly installments thereafter. Each vesting date requires continued employment.
IN8bio (INAB) will present at the Sidoti Small-Cap Virtual Conference on Thursday, September 24, 2026, at 1:00 p.m. ET.
Chief Executive Officer and Co-Founder William Ho will deliver a company presentation and hold one-on-one investor meetings during the September 23–24, 2026 event. The presentation will cover IN8bio’s differentiated γδ T cell platform, its pipeline, lead T cell engager program INB-619, and clinical-stage oncology programs. A live webcast and subsequent replay will be accessible via the Investors section of IN8bio’s website, with registration hosted on the Sidoti Zoom webinar platform.
IN8bio (INAB) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14, 2026, in New York.
Chief Executive Officer and Co-Founder William Ho will present at 10:00 a.m. ET in the Kennedy II room on the 4th floor of the Lotte New York Palace Hotel. Ho and other members of the management team will also hold one-on-one meetings with investors throughout the conference. A live webcast of the presentation, along with a replay after the event, will be accessible via the Investors section of IN8bio’s website.
IN8bio (INAB) appointed Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development, adding a veteran γδ T cell and T cell engager specialist to its leadership team. She brings 20 years of drug discovery and development experience across oncology, immunology, cell therapies, antibodies and engager-based therapeutics.
Polyakova previously served as Chief Scientific Officer at LAVA Therapeutics and LIfT Biosciences and was Scientific Founder and Head of Discovery at Adaptate Biotherapeutics, a γδ T cell engager spinout of GammaDelta Therapeutics that was acquired by Takeda. In her new role, she will help lead IN8bio’s R&D strategy, with a focus on strengthening and accelerating its γδ T cell engager programs and expanding the INB-600 platform across oncology and autoimmune indications.
IN8bio (Nasdaq: INAB) reported that its Board Compensation Committee granted one new employee a nonqualified stock option to purchase an aggregate of 4,000 shares of common stock under the company’s 2026 Inducement Plan, effective August 3, 2026, as an inducement award under Nasdaq Listing Rule 5635(c)(4).
The option vests over four years: 25% on the employee’s first work anniversary and the remaining 75% in 36 equal monthly installments, subject to continued employment. IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager product candidates, including INB-600, INB-100, and INB-200/400.
IN8bio (Nasdaq: INAB) reported second quarter 2026 results and key clinical advances in its γδ T cell and γδ T cell engager portfolio. The INB-600 platform progressed with lead CD19-targeting engager INB-619 moving into IND-enabling studies after preclinical data showing complete B cell depletion, robust γδ T cell expansion and minimal CRS-associated cytokines, with initial in vivo data expected in the second half of 2026.
For newly diagnosed glioblastoma, updated DeltEx™ DRI data showed mPFS of 13.0 months vs 6.6 months for standard-of-care and mOS exceeding 19.5 months vs 13.2 months, with no DLTs, CRS or ICANS observed. Immune profiling showed an 18-fold increase in intratumoral CD8+ T cells and a 90% reduction in immunosuppressive granulocytes. As of June 30, 2026, cash was $18.0 million; Q2 R&D expenses were $2.5 million, G&A $2.4 million, and net loss $4.8 million ($0.25 per share), modestly improved from the prior-year quarter.
IN8bio (Nasdaq: INAB) reported peer-reviewed Phase 1 data for its DeltEx DRI (INB-200) in newly diagnosed glioblastoma, published in Journal of Clinical Oncology.
Repeat-dose patients showed median progression-free survival of 16.1 months vs ~6.9 months standard of care, with no dose-limiting toxicities.
IN8bio (NASDAQ: INAB)/b) announced publication of a review in titled “Harnessing γδ T cells through engineering and combination therapies.” The article, co-authored by CSO Lawrence Lamb, PhD, reviews γδ T cell engineering, T cell engagers, CAR-γδ T cells and cytokine-armored cells.
It discusses combination strategies with checkpoint inhibitors, chemotherapy, cytokines and bispecific antibodies, the potential for allogeneic “off-the-shelf” γδ T therapies with limited GvHD risk, and growing clinical evidence in solid tumors and hematologic cancers.
IN8bio (NASDAQ:INAB) reported updated data from its INB-200 Phase 1 and INB-400 Phase 2 studies of repeat-dose DeltEx DRI in newly diagnosed glioblastoma at ASCO 2026.
Median progression-free survival reached 13.0 months and median overall survival currently exceeds 19.5 months, versus 6.6 and 13.2 months for standard-of-care alone, with 43% vs 20% 24‑month survival and a generally well-tolerated safety profile.
IN8bio (Nasdaq: INAB)/b) reported Q1 2026 results and program updates on May 7, 2026. Key clinical highlights include a reported for repeat-dose GBM patients versus 6.6 months for SOC (+97%) and mOS of 17.2+ months. Cash was $21.9M as of March 31, 2026.
The company advanced its INB-619 γδ T cell engager into IND-enabling studies with initial animal data expected in 2026 and will present updated mOS data at ASCO 2026.